BlackRock Fund Advisors’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

BlackRock Fund Advisors’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$67.7M	Buy	853,285 +83,416	+11%	+$6.06M	0.01%	1479
2016 Q3	$53.9M	Buy	769,869 +358,134	+87%	+$19.8M	0.01%	1523
2016 Q2	$16M	Buy	411,735 +2,501	+0.6%	+$104K	﹤0.01%	2158
2016 Q1	$16.6M	Buy	409,234 +16,137	+4%	+$1.02M	﹤0.01%	2086
2015 Q4	$34.9M	Buy	393,097 +188,598	+92%	+$14.9M	0.01%	1720
2015 Q3	$15.1M	Sell	204,499 -980	-0.5%	-$81.5K	﹤0.01%	2164
2015 Q2	$16.6M	Buy	205,479 +196,603	+2,215%	+$12.8M	﹤0.01%	2226
2015 Q1	$372K	Buy	8,876 +5,645	+175%	+$160K	﹤0.01%	3316
2014 Q4	$50K	Buy	+3,231	New	+$41.3K	﹤0.01%	3673
2014 Q2	–	Sell	-78,665	Closed	-$1M	–	3902
2014 Q1	$1M	Buy	+78,665	New	+$1.07M	﹤0.01%	3191

Other funds holding EGRX

PAI

ProQuest Associates IV Naples, Florida $53M AUM 3.35% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

HEC

Hudson Executive Capital New York $151M AUM 60.14% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

JAM

JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock Fund Advisors's EGRX Position: Q4 2016 in Review

BlackRock Fund Advisors increased its Eagle Pharmaceuticals, Inc. (EGRX) stake by 11% in Q4 2016, buying an estimated $6.06M and bringing the position to 853,285 shares worth $67.7M. The position accounts for 0.01% of the portfolio, ranked #1479.

BlackRock Fund Advisors first reported a position in EGRX in Q1 2014 and has held it in 10 quarters since. 149 funds tracked by Wall St. Rank hold EGRX as of Q4 2016.

BlackRock Fund Advisors held 853,285 shares of Eagle Pharmaceuticals, Inc. worth $67.7M as of Q4 2016.
BlackRock Fund Advisors bought 83,416 Eagle Pharmaceuticals, Inc. shares in Q4 2016, an estimated $6.06M.
Eagle Pharmaceuticals, Inc. made up 0.01% of BlackRock Fund Advisors's portfolio in Q4 2016, its #1479 holding.
BlackRock Fund Advisors first reported a position in Eagle Pharmaceuticals, Inc. in Q1 2014 and has held it in 10 quarters since.
149 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q4 2016.

Based on BlackRock Fund Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.